Interview Archives before 2011 @ MSAPR Partners

Archive Interviews through 2022

Issue 367: April 1, 2011 Scott Minick, President and CEO, BIND Biosciences, on the company’s therapeutic targeted nanoparticle technology.	Issue 366: March 25, 2011 Robert Shore, M.D., CEO, and Timothy Sullivan, Executive Vice President, Cornerstone Pharmaceuticals, on the company’s drug delivery technology targeting cancer cell metabolism.
Issue 364: March 11, 2011 Robert L. Kirkman, M.D., President and CEO, and Scott Peterson, Ph.D., Vice President of Research and Development, Oncothyreon, on the company’s PI3K inhibitor.	Issue 363: March 4, 2011 Ernest Wong, Ph.D., M.B.A., Vice President, YM Biosciences, about the company’s JAK inhibitor program in myelofibrosis.
Issue 362: February 25, 2011 Masayuki Yazawa, Ph.D., Postdoctoral Research Fellow, Stanford University, on the use of iPS cells to treat Timothy Syndrome.	Issue 361: February 18, 2011 William S. Marshall, Ph.D. President and CEO of miRagen Therapeutics, about the company’s miRNA-targeted drugs.
Issue 358: January 28, 2011 Arthur Sands, M.D., Ph.D., President and CEO, Lexicon Pharmaceuticals, about the company’s development programs and partnering strategy.	Issue 356: January 14, 2011 Katrine Bosley, CEO of Avila Therapeutics, about the company’s discovery platform for targeted covalent drugs.
Issue 354: December 23, 2010 Robert Kneller, J.D., M.D., M.P.H., Professor, Research Center for Advanced Science and Technology (RCAST), University of Tokyo, on the differences between pharma and academia in drug discovery innovation.	Issue 353: December 17, 2010 Aris Persidis, PhD., President and Co-Founder, Biovista Inc., on using mechanism of action to predict safety and efficacy.
Issue 351: December 3, 2010 Thomas Hughes, Ph.D., President and CEO of Zafgen Inc., on the company’s lead candidate compound that promotes sustained weight loss through MetAP2 inhibition	Issue 350: November 19, 2010 Eggehard Holler, Ph.D., University of Regensburg, Julia Ljubimova, M.D., Ph.D., Cedars-Sinai Medical Center, and Maurizio Vecchione, CEO, Arrogene Nanotechnology, on a nanoconjugate technology for treating brain …
Issue 348: November 5, 2010 John E. Wennberg, M.D., M.P.H., Peggy Y. Thomson Professor in the Evaluative Clinical Sciences, Dartmouth Medical School, on a rational approach to supply and demand in medicine.	Issue 346: October 22, 2010 Tillman U. Gerngross, Ph.D., CEO of Adimab Inc., on the company’s novel antibody discovery platform.
Issue 343: October 1, 2010 Kobi M. Sethna, President and CEO, Nereus Pharmaceuticals, on leveraging marine microbes as a source of novel pharmaceutical agents.	Issue 342: September 24, 2010 Richard L. Atkinson, M.D., Clinical Professor of Pathology, Virginia Commonwealth University, and President, Obetech, LLC, on the evidence for a causal link between AD36 and obesity.
Issue 341: September 17, 2010 Kathleen Sereda Glaub, President, Plexxikon, on the company’s lead drug candidate for melanoma.	Issue 337: August 20, 2010 Harald Fricke, M.D., Ph.D., CMO and COO, Apogenix, on an innovative therapeutic approach to treating glioblastoma.
Issue 336: August 6, 2010 Stephen Engle, Chairman and CEO, XOMA, on developing a therapeutic antibody-based approach to diabetes treatment.	Issue 334: July 23, 2010 Soichi Matsuno, Advisor, Eisai Co., Ltd., on how the company’s pioneering spirit has contributed to its global expansion.
Issue 333: July 15, 2010 Maria L. Maccecchini, Ph.D., President & CEO, QR Pharma, on an approach to inhibiting amyloid formation in targeting mild cognitive impairment and Alzheimer’s disease.	Issue 332: July 7, 2010 Marc Cantillon, M.D., Director of the Coalition Against Major Diseases at the Critical Path Institute, on accelerating Alzheimer’s drug development through data collaboration.
Issue 328: June 4, 2010 Gordon McCauley, President and CEO, Allon Therapeutics Inc., on targeting neurodegenerative diseases with activity-dependent neuroprotective protein.	Issue 326: May 21, 2010 Robert Gould, Ph.D., President and CEO, and Jason Rhodes, EVP and Chief Business Officer of Epizyme, on transforming cancer therapy via HMT inhibition.
Issue 325: May 14, 2010 Tom Smart, Chairman and CEO, AnaptysBio, on leveraging a novel platform for antibody generation.	Issue 322: April 23, 2010 Roger H. Unger, M.D., Professor of Internal Medicine, University of Texas South Western Medical Center, on the comparison of leptin and insulin levels in mouse models of type 1 diabetes.
Issue 321: April 16, 2010 Adam Bosworth, Founder and CTO of Keas, on using intelligent computing to improve patient outcomes.	Issue 316: March 12, 2010 Christopher S. Meldrum, President, Pique Therapeutics, on non-immunogenic cancer treatment using allogenic vaccine therapies.
Issue 314: February 26, 2010 Andrew M. Thompson, Co-Founder and CEO, Proteus Biomedical, on the company’s advancements in intelligent medicine.	Issue 312: February 12, 2010 Stephen H. Friend, M.D., Ph.D., President, CEO and Co-Founder, Sage Bionetworks, on the development of a shared data repository of clinical data to improve disease modeling.
Issue 309: January 22, 2010 Alpheus Bingham, Ph.D., Founder and Director, InnoCentive Inc., on an incentive-based open innovation model for helping organizations solve research problems.	Issue 305: December 18, 2009 Per Olof Wallström, President and CEO, and Erika Söderberg Johnson, CFO, Karo Bio, on the development of innovative therapeutics targeting nuclear receptors.
Issue 304: December 11, 2009 Joshua Kazam, President and CEO, Nile Therapeutics, on the company’s application of natriuretic peptides to treat heart failure.	Issue 303: December 4, 2009 Kees Been, President and CEO, EnVivo Pharmaceuticals, on enhancing cognitive function in Alzheimer’s disease and schizophrenia patients.
Issue 302: November 20, 2009 Benjamin Heywood, Co-Founder and President, PatientsLikeMe, on the company’s platform for connecting patients and pharma through social networking.	Issue 301: November 13, 2009 Randall L. Carpenter, M.D., Co-Founder, President and CEO, Seaside Therapeutics, on the development of novel therapies for Fragile X Syndrome.
Issue 300: November 6, 2009 Joseph P. Pieroni, CEO, Daiichi Sankyo Inc., on the company’s marketing strategy for Effient.	Issue 299: October 30, 2009 Judy Mikovits, Ph.D, Director of Research at the Whittemore Peterson Institute, on the correlation between XMRV and Chronic Fatigue Syndrome.
Issue 296: October 9, 2009 David Rose, CEO, Vitality, on GlowCaps, the company’s breakthrough technology to promote medicine adherence.	Issue 295: October 2, 2009 Jennifer A. Low, MD, PhD, Global Clinical Lead for GTC-0449, Genentech, on Promising Early Clinical Results for a Hedgehog Inhibitor in Cancer.
Issue 293: September 18, 2009 Julia P. Gregory, President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.	Issue 290: August 28, 2009 Shingo Kajimura, Ph. D., Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.
Issue 289: August 21, 2009 Robert H. Uhl, Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.	Issue 288: August 14, 2009 Dr. Gail Naughton, CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.
Issue 286: July 31, 2009 Neil Warma, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.	Issue 283: July 10, 2009: Vijay B. Samant, President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.
Issue 282: June 26, 2009 Robert Gatenby, M.D., Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.	Issue 281: June 19, 2009 Vince Kuraitis, Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.
Issue 280: June 12, 2009 Gregory Perry, Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.	Issue 278: May 29, 2009 Saeid Akhtari, Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.
Issue 277: May 22, 2009 Shawn Lyndon, Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.	Issue 276: May 15, 2009 Eric Elliott, President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.
Issue 275: May 8, 2009 Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.	Issue 270: April 3, 2009 Bruce S. Auerbach, M.D., FACEP, President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.
Issue 269: March 27, 2009: Yoshimi Kuroiwa, Ph.D., Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.	Issue 264: February 20, 2009 Vincent Mutel, Ph.D., Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).
Issue 263: February 13, 2009 Jason Hwang, M.D., Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.	Issue 260: January 13, 2009 Scott Weir, PharmD, Ph.D., Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).
Issue 259: January 16, 2009 Mollie Shields-Uehling, President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.	Issue 255: December 5, 2008 Les Jordan, Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.
Issue 254: Nobember 21, 2008 Thomas Neyarapally, Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.	Issue 252: Nobember 7, 2008 Robert S. Becker, Ph.D., MBA, Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.
Issue 251: October 31, 2008 James J. O’Mara, Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..	Issue 248: October 10, 2008 Hironori Hozoji, Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.
Issue 246: September 26, 2008 David Steinberg, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.	Issue 245: September 19, 2008 Danong Chen, Ph.D., President and CEO, Theranostics Health, on protein profiling and targeted therapies.
Issue 244: September 12, 2008 Javier Gonzalez-Maeso, Ph.D., Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.	Issue 241: August 22, 2008: Ellen Coleman, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.
Issue 240: August 8, 2008 Nicholas J. Seay, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.	Issue 239: August 1, 2008 Jacqueline A. French, MD, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.
Issue 233: June 13, 2008 Howard Martin Fillit, M.D., Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.	Issue 231: May 30, 2008 Jayakrishna Ambati, M.D., Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.
Issue 227: May 2, 2008 Keizo Koya, Ph.D., Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.	Issue 225: April 18, 2008 Anthony J. Varano, Jr., Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.
Issue 224: April 11, 2008: David G. Stevenson, S.M., Ph.D., Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.	Issue 223: April 4, 2008 Joe Dougherty, Ph.D., Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.
Issue 221: March 20, 2008 Adam J. Fein, Ph.D., Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.	Issue 217: February 22, 2008 Bernhardt L. Trout, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.
Issue 215: February 8, 2008 Akiko Yabuuchi, Ph.D., Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.	Issue 213: January 25, 2008 Joshua J. Spooner, PharmD, MS, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.

Issue 293: September 18, 2009 Julia P. Gregory, President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.	Issue 290: August 28, 2009 Shingo Kajimura, Ph. D., Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.
Issue 289: August 21, 2009 Robert H. Uhl, Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.	Issue 288: August 14, 2009 Dr. Gail Naughton, CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.
Issue 286: July 31, 2009 Neil Warma, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.	Issue 283: July 10, 2009: Vijay B. Samant, President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.
Issue 282: June 26, 2009 Robert Gatenby, M.D., Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.	Issue 281: June 19, 2009 Vince Kuraitis, Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.
Issue 280: June 12, 2009 Gregory Perry, Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.	Issue 278: May 29, 2009 Saeid Akhtari, Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.
Issue 277: May 22, 2009 Shawn Lyndon, Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.	Issue 276: May 15, 2009 Eric Elliott, President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.
Issue 275: May 8, 2009 Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.	Issue 270: April 3, 2009 Bruce S. Auerbach, M.D., FACEP, President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.
Issue 269: March 27, 2009: Yoshimi Kuroiwa, Ph.D., Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.	Issue 264: February 20, 2009 Vincent Mutel, Ph.D., Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).
Issue 263: February 13, 2009 Jason Hwang, M.D., Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.	Issue 260: January 13, 2009 Scott Weir, PharmD, Ph.D., Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).
Issue 259: January 16, 2009 Mollie Shields-Uehling, President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.	Issue 255: December 5, 2008 Les Jordan, Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.
Issue 254: Nobember 21, 2008 Thomas Neyarapally, Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.	Issue 252: Nobember 7, 2008 Robert S. Becker, Ph.D., MBA, Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.
Issue 251: October 31, 2008 James J. O’Mara, Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..	Issue 248: October 10, 2008 Hironori Hozoji, Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.
Issue 246: September 26, 2008 David Steinberg, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.	Issue 245: September 19, 2008 Danong Chen, Ph.D., President and CEO, Theranostics Health, on protein profiling and targeted therapies.
Issue 244: September 12, 2008 Javier Gonzalez-Maeso, Ph.D., Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.	Issue 241: August 22, 2008: Ellen Coleman, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.
Issue 240: August 8, 2008 Nicholas J. Seay, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.	Issue 239: August 1, 2008 Jacqueline A. French, MD, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.
Issue 233: June 13, 2008 Howard Martin Fillit, M.D., Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.	Issue 231: May 30, 2008 Jayakrishna Ambati, M.D., Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.
Issue 227: May 2, 2008 Keizo Koya, Ph.D., Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.	Issue 225: April 18, 2008 Anthony J. Varano, Jr., Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.
Issue 224: April 11, 2008: David G. Stevenson, S.M., Ph.D., Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.	Issue 223: April 4, 2008 Joe Dougherty, Ph.D., Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.
Issue 221: March 20, 2008 Adam J. Fein, Ph.D., Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.	Issue 217: February 22, 2008 Bernhardt L. Trout, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.
Issue 215: February 8, 2008 Akiko Yabuuchi, Ph.D., Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.	Issue 213: January 25, 2008 Joshua J. Spooner, PharmD, MS, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.

Issue 208: December 14, 2007 Boro Dropulic, Ph.D., M.B.A, Founder and Chief Executive Officer, Lentigen, on the uses and advantages of his company’s Lentiviral Vector Platform.	Issue 205: November 16, 2007 Gerald Bernstein, M.D., F.A.C.P., Vice President for Medical Affairs, Generex Biotechnology, on Generex’s Oral-lyn insulin product and the advantages of buccal delivery.
Issue 204: November 9, 2007 Elizabeth Haanes, Ph.D., Director, Sterne, Kessler, Goldstein & Fox P.L.L.C., on newly proposed Patent Office rules that would pose a hardship for the pharmaceutical industry.	Issue 203: November 2, 2007 Michael J. Krische, Ph.D., Professor, Department of Chemistry and Biochemistry, University of Texas at Austin, on a byproduct-free method of creating carbon-carbon bonds through hydrogenation.
Issue 200: October 12, 2007 William C. Crawford , Director of Industry Relations, Children’s Hospital Informatics Program, on creating a market for personally-controlled health records.	Issue 199: October 5, 2007 Gokhan S. Hotamisligil, M.D., Ph.D. , Chair, Department of Genetics and Complex Diseases, and J.S. Simmons Professor of Genetics & Metabolism, Harvard School of Public Health, on therapies at the interface of metabolic and inflammatory diseases.
Issue 198: September 28, 2007 Daniel J. Carlat, M.D. , Assistant Clinical Professor of Psychiatry, Tufts University School of Medicine, and Editor-in-Chief, The Carlat Psychiatry Report, on industry sponsorship of continuing medical education.	Issue 197: September 21, 2007 Paul Burn, Ph.D. , Senior Vice President of Research & Development, Juvenile Diabetes Research Foundation (JDRF), on JDRF’s increased focus on translational and clinical research.
Issue 196: September 14, 2007 Sara Rosenbaum, Chair, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, on the SCHIP reauthorization bill.	Issue 194: August 31, 2007 Frank Burroughs , President, Abigail Alliance for Better Access to Developmental Drugs, on his organization’s push for ACCESS legislation.
Issue 192: August 10, 2007 Pieter Muntendam M.D. , President and CEO, and Robert N. McBurney, Ph.D., Senior Vice President, Research & Development, and Chief Scientific Officer, BG Medicine, on creating biomarkers as decision tools for molecular medicine.	Issue 189: July 20, 2007 J. Scott Tarrant , VP of Business Development, Xceleron Inc., on prioritizing compounds with human PK data through microdosing studies.
Issue 188: July 13, 2007 Barry J. Schindler, Shareholder, Greenberg Traurig, LLP, on unresolved points of contention in the proposed patent reform bill.	Issue 187: July 6, 2007 Eileen Hilton, M.D. , President and CEO, Biomedical Research Alliance of New York (BRANY), on BRANY’s one-stop service for multi-center clinical trials.
Issue 186: June 29, 2007 Naomi Aronson, Ph.D. , Executive Director, Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC), on technology assessments and comparative effectiveness reviews.	Issue 182: June 29, 2007 Michael Milburn, Ph.D. , Chief Scientific Officer, Metabolon, Inc., on using metabolomics in biomarker discovery and compound profiling.
Issue 179: May 11, 2007 Stuart W. Peltz, Ph.D. , President and CEO, PTC Therapeutics, on his company’s approach of using small molecules to regulate protein synthesis.	Issue 178: May 4, 2007 Bruce W. MacLennan, Partner, Herrick Feinstein LLP, on negotiating licensing deals with biotech companies.
Issue 176: April 20, 2007 Daniel B. Ravicher , President and Executive Director, Public Patent Foundation, on challenging bad patents to serve the public interest.	Issue 175: April 13, 2007 Jacques E. Rossouw, M.D. , Chief of Women’s Health Initiative Branch, National Heart, Lung, and Blood Institute, NIH, on refining treatment recommendations for hormone therapy.
Issue 174: March 30, 2007 Wayne Koberstein , Consultant, on trends and developments among some of the key companies within the pharmaceutical industry.	Issue 172: March 16, 2007 William A. Sarraille , Partner, Sidley Austin LLP, on the potential impact of CMS’s proposed rules regarding Average Manufacturer Price (AMP) in Medicaid
Issue 171: March 9, 2007 Mark Kessel , Co-Founder and Managing Director, Symphony Capital, on Symphony Capital’s partnership approach to financing the development of early clinical-stage compounds.	Issue 169: February 23, 2007 William L. Warren , Partner, Sutherland Asbill & Brennan LLP, on Representative Waxman’s proposed bill on follow-on biologics.
Issue 167: February 9, 2007 Lynn E. Eccleston , Attorney, McGuire Woods LLP, on the ramifications of the Supreme Court’s decision on declaratory judgments in MedImmune v. Genentech.	Issue 164 and 165: January 19 and 26, 2007 Shin-Ichiro Imai, M.D., Ph.D. Assistant Professor, Molecular Biology and Pharmacology, Washington University School of Medicine, on research into Sir2 and longevity.
Issue 161: December 22, 2006 Kenneth A. Getz, Senior Research Fellow, Tufts Center for the Study of Drug Development, on factors affecting speed and efficiency in clinical development.	Issue 160: December 15, 2006 Louis A. Tartaglia, Ph.D., Senior Vice President and General Manager of Drug Repositioning and Selection, Gene Logic, on Gene Logic’s drug repositioning business.
Issue 159: December 8, 2006 Gary P. Pisano, Professor, Harvard Business School, on his new book on the biotechnology industry, Science Business.	Issue 156: November 10, 2006 Richard P. Burgoon, Jr., CEO, Aeolus Pharmaceuticals, Inc., on catalytic antioxidants and Aeolus’ corporate strategy.
Issue 155: November 3, 2006 Marc Fisher, MD, Professor of Neurology, University of Massachusetts Medical School, on new approaches for clinical development of stroke therapies.	Issue 153: October 20, 2006 Eric Button, President and Managing Director, The BioMarker Group, on integrating biomarkers into drug development programs.
Issue 152: October 13, 2006 Alan Goldhammer, Associate Vice President Regulatory Affairs, Pharmaceutical Research and Manufacturers of America, on PhRMA’s views of the Institute of Medicine’s recommendations to improve drug safety.	Issue 151: October 6, 2006 Arthur M. Krieg, M.D., Senior Vice President, Research and Development, and Chief Scientific Officer, Coley Pharmaceutical Group, on Coley’s development of CpG oligonucleotide immunotherapeutics.
Issue 150: September 29, 2006 Brian P. Murphy, Partner, Morgan, Lewis & Bockius LLP, on unresolved issues in Hatch-Waxman settlement agreements.	Issue 149: September 22, 2006 Mihael H. Polymeropoulos, M.D., CEO, and Chip Clark, Chief Business Officer, Vanda Pharmaceuticals, on Vanda’s genomics-based approach to product differentiation in the market for CNS treatments.
Issue 148: September 15, 2006 Gokhan S. Hotamisligil, M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, on chemical chaperones that suppress ER stress as potential treatments for diabetes.	Issue 147: September 8, 2006 Fumihiko Urano, M.D., Assistant Professor, University of Massachusetts Medical School, on the role of IRE1 in insulin biosynthesis in response to ER stress.
Issue 145: August 25, 2006 Bruce E. Schneider, Executive Vice President and Chief of Operations, Wyeth Research, on Wyeth’s adoption of a “learn and confirm” approach to clinical development.	Issue 144: August 11, 2006 Duane Thurman, Director, Prescription Drug Program, Washington State Health Care Authority, on the state’s preferred drug list and efforts to promote evidence-based, cost-effective prescribing behavior.
Issue 143: August 4, 2006 Craig Atwood, Assistant Professor, Department of Medicine, University of Wisconsin, on the Reproductive-Cell Cycle Theory of Aging.	Issue 141: July 21, 2006 Hiromi Yoshikawa, Chairman and CEO, Otsuka America Pharmaceutical, Inc., on the expansion of Otsuka’s pharmaceutical business in the US.
Issue 140: July 14, 2006: Daniel L. Weiner, Senior Vice President, Software Products, Pharsight Corporation, on Pharsight’s CRADA with the FDA and the infrastructure required for modeling and simulation in clinical development.	Issue 139: July 7, 2006 Garo H. Armen, Chairman and CEO, Antigenics Inc., on Oncophage, an experimental cancer vaccine using heat shock proteins.
Issue 138: June 30, 2006 Donald A. Berry, Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, on the use of Bayesian statistical methods in clinical development.	Issue 136: June 16, 2006 John E. McDonough, Executive Director, Health Care For All, on new legislation designed to reduce the number of people without health insurance in Massachusetts.
Issue 135: June 9, 2006 Robert J. Feeney, Jr., President & CEO, MedVantx, on his company’s Sample Centers that dispense free generic drug samples.	Issue 134: June 2, 2006 Dr. Anthony Hayward, Director, Division of Clinical Research Resources, National Center for Research Resources, NIH, on a new Roadmap initiative to promote clinical research.
Issue 133: May 26, 2006 Dr. Steve E. Phurrough, Director, Coverage & Analysis Group, CMS, on National Coverage Determinations for Part B Drugs in Medicare.	Issue 132: May 19 , 2006 Dr. Randall S. Stafford, Assistant Professor of Medicine, Stanford Prevention Research Center, on new research in off-label prescribing patterns.
Issue 131: May 12, 2006 Dr. Bruce Silver, VP of Global Product Development Services in Oncology, PRA International, on issues in cancer drug development.	Issue 129: April 21, 2006 Dr. John T. Santini, Jr., President, MicroCHIPS, Inc., on implantable devices for drug delivery.
Issue 128: April 13, 2006 Diana Conmy, Corporate Director of Market Insights at IMS Health, on key developments for the pharmaceutical industry in 2005.	Issue 127: April 7, 2006 Paul J. Hastings, President and Chief Executive Officer of Oncomed, Inc., on drugs to target cancer stem cells.
Issue 126: March 31, 2006 Dr. David Sinclair, Associate Professor of Pathology at Harvard Medical School, on the effects of SIR2 on the aging process.	Issue 125: March 24, 2006 Dr. Abner L. Notkins, Chief of Experimental Medicine for the National Institute of Dental and Craniofacial Research at the NIH, on the use of autoantibodies in predictive medicine.
Issue 124: March 17, 2006 Michael Valentino, Chief Consultant, PBM Strategic Healthcare Group, VA, on the VA�fs national formulary.	Issue 123: March 10, 2006 J.D. Kleinke, Chairman & Executive Director, Omnimedix Institute, on obstacles to the development of a viable HIT system.
Issue 121:February 24, 2006 Dr. Barry Davis, Principal Investigator & Director, ALLHAT Clinical Trials Center, on using the landmark ALLHAT results to change prescribing behavior.	Issue 120: February 17, 2006 Dr. Gerald Reaven, Professor Emeritus (Active) of Medicine, Stanford University, on insulin resistance syndrome.
Issue 117: January 27, 2006 Dr. Stanley Ip, Project Leader, and Dr. Peter Bonis, Primary Technical Expert, Tufts-New England Medical Center Evidence-based Practice Center, on the comparative effectiveness of treatments for gastroesophageal reflux disease.	Issue 116: January 20, 2006 Dr. Timothy Anderson, Senior Pharmaceutical Analyst, Prudential Equity Group, LLC, on pharmaceutical patent expirations in 2006.
Issue 115:January 13, 2006 Dr. Kazuko Nishikura, Professor, Gene Expression and Regulation Program, The Wistar Institute, on her research into RNA editing and microRNA.	Issue 113: December 22, 2005 Dr. Alice M. Rivlin, Senior Fellow in Economic Studies, The Brookings Institution, on the fiscal sustainability of Medicare spending.
Issue 112:December 16, 2005 James M. Karis, President & CEO, Entelos, Inc., on the role of in silico modeling in drug development.	Issue 110: December 2, 2005 Jerry Avorn, Professor of Medicine, Harvard Medical School, on academic detailing and physician prescribing behavior.
Issue 109: November 18, 2005 Kenneth I. Kaitin, Director, Tufts Center for the Study of Drug Development, on recent drug output trends.	Issue 108: November 11, 2005 Joan Alker, Senior Researcher, Georgetown Health Policy Institute, on Florida’s proposed changes to the state Medicaid program.
Issue 107: November 4, 2005 Joshua Shinoff, Licensing Officer, Office of Technology Licensing, on technology transfer at UC Berkeley.	Issue 105: October 21, 2005 John A. Scarlett, President and CEO, Tercica, on the company’s newly approved treatment for short stature.
Issue 103: October 7, 2005 Jean R. Slutsky, Director, Center for Outcomes and Evidence, on MMA provisions affecting the Agency for Healthcare Research and Quality.	Issue 102: September 30, 2005 Dara A. Corrigan, Partner, Arnold & Porter, on new MMA priorities for the Inspector General’s Office at HHS.
Issue 101: September 23, 2005 Larry Gold, CEO & Chairman of the Board, SomaLogic, Inc., on the uses of aptamer technology.	Issue 100: September 16, 2005 Larry D. Sasich, Staff Pharmacist, Public Citizen, on drug safety issues at the FDA.
Issue 99: September 9, 2005 Mark Heesen,President, National Venture Capital Association, on venture capital financing trends in the biotech industry.	Issue 98: September 2, 2005 Dr. John A. Gans, EVP and CEO, American Pharmacists Association, on the role of pharmacists in improving drug safety.
Issue 97: August 26, 2005 David Largaespada,Associate Professor, University of Minnesota Cancer Center, on a new method of cancer-gene identification using the Sleeping Beauty transposon.	Issue 96: August 12, 2005 Makoto Nishimura, President and CEO of Astellas Pharma US, Inc. on Astellas’s strategy in U.S. market.
Issue 93: July 22, 2005 Sharon Anglin Treat, Executive Director, National Legislative Association on Prescription Drug Prices, on state-level initiatives to reduce prescription drug prices..	Issue 92: July 15, 2005 Dr. Moriya Tsuji, Associate Professor, Aaron Diamond AIDS Research Center, Rockefeller University, on the discovery of new antigens that bind to the CD1d receptor and activate NKT cells.
Issue 91: July 8, 2005 Larry McComber, VP Contract and Program Services, Novation LLC, on GPO contracting for prescription drugs.	Issue 90: July 1, 2005 Robert K. Passikoff, Founder and President, Brand Keys, Inc., on DTC corporate and product brand promotion.
Issue 89: June 24, 2005 Jeffrey I.D. Lewis, Partner, Patterson Belknap Webb & Tyler LLP, on the impact of the Integra v. Merck decision on pharmaceutical research.	Issue 88: June 17, 2005 Shabbir Dahod, President and CEO, SupplyScape Corporation, on developing an electronic pedigree for the pharmaceutical supply chain.
Issue 86: May 27, 2005 Michael Rosen, Chairman and CEO, Immune Cell Therapy, Inc., on the life sciences hub in the Midwest.	Issue 84: May 13, 2005 Gary Zammit, President and CEO, Clinilabs, Inc., on progress in developing treatments for sleep disorders.
Issue 80: April 15, 2005 Frank M. Rapoport, Partner, McKenna Long & Aldridge LLP, on the BioShield legislation and the development of a biodefense industry.	Issue 78: April 1, 2005 Steve Powell, Vice President of Worldwide Sales, Phase Forward, Incorporated, on the use of electronic data capture in clinical trials
Issue 77: March 25, 2005 Christopher Watts, Staff Fellow, Center for Drug Evaluation and Research, FDA, on moving to real time release with PAT.	Issue 76: March 18, 2005 Daniel Devine, President and CEO, Acceptys, Inc., on shifting from humanized to fully-human monoclonal antibodies.
Issue 75: March 11, 2005 Alton C. Morgan, Chairman and President, InNexus Biotechnology, Inc., on the development of SuperAntibodies.	Issue 73: February 25, 2005 Paul Cusenza, Vice President, Alliance Management, Perlegen Sciences, Inc., on Perlegen’s approach to high-density, whole genome SNP genotyping.
Issue 72: February 18, 2005 Derek Guyton, Principal, Mercer Human Resources Consulting, on how employer-sponsored retiree drug benefits are being affected by the MMA.	Issue 69: January 28, 2005 Steven H. Sklar, Partner, Leydig, Voit & Mayer, Ltd., on the Teva v. Pfizer decision on declaratory judgment actions.
Issue 68: January 21, 2005 Vera Hassner Sharav, President, Alliance for Human Research Protection, on how industry practices in clinical trials have led to an erosion of public trust.	Issue 65: December 24, 2004 Maxine Gowen, Managing Partner, SR One, on the investment approach of a venture capital subsidiary of a major pharmaceutical company.
Issue 64: December 17, 2004 Jennifer Covich Bordenick, MA, Director of Strategic Programs, eHealth Initiative, on the adoption of e-prescribing.
Issue 63: December 10, 2004 John Santa, Medical Director of the Center for Evidence-based Policy at Oregon Health and Science University, on state initiatives to create a transparent drug evaluation system for more cost-effective drug spending.	Issue 61: November 19, 2004 J. David Haddox, Vice President, Risk Management & Health Policy, Purdue Pharma, on a government-aided, multifaceted approach to reduce the potential for abuse of prescription pain treatments.
Issue 59: November 5, 2004 Mark Merritt, President and CEO, Pharmaceutical Care Management Association, on the role of pharmacy benefit managers in the Medicare prescription drug benefit.	Issue 57: October 22, 2004 Joseph S. McCracken, Vice President, Business Development, Genentech, Inc., on Genentech’s approach to R&D and commercialization partnerships.
Issue 56: October 15, 2004 Kathleen Jaeger, President and CEO, Generic Pharmaceutical Association, on the scientific advancements facilitating regulatory evaluations of biogenerics.	Issue 55: October 8, 2004 Richard C. Aulatta, President, R.C. Auletta and Co., on Merck’s handling of the Vioxx recall.
Issue 52: September 17, 2004 Michael Krensavage, Senior Vice President, Equity Research, Raymond James & Associates, on Schering-Plough’s turnaround strategy.	Issue 51: September 10, 2004 Richard D. Kelly, Senior Partner, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., on issues relating to authorized generics.
Issue 49: August 20, 2004 Jeffrey Aronin, Founder, President and COO, Ovation Pharmaceuticals, on Ovation’s niche market business strategy.	Issue 48: August 13, 2004 Nobuya Oka, Executive Vice President, Takeda Pharmaceuticals North America, on Takeda’s strategy in the U.S. market.
Issue 47: August 6, 2004 Reeta Roy, Vice President, Global Citizenship and Policy, Abbott Laboratories, on Abbott’s AIDS initiatives in developing countries.	Issue 45: July 23, 2004 Kevin Outterson, Associate Professor of Law, West Virginia University, on the impact of the Australia-U.S. Free Trade Agreement on the market for pharmaceuticals.
Issue 44: July 16, 2004 Vamsi K. Mootha, M.D., Assistant Professor, Harvard Medical School, on the team-science approach to biomedical research.	Issue 43: July 9, 2004 Michael M. Gottesman, M.D., Deputy Director for Intramural Research, NIH, on intramural research at the NIH.
Issue 42: July 2, 2004 Barry Greene, Chief Operating Officer, Alnylam Pharmaceuticals, on RNAi therapeutics.	Issue 41: June 25, 2004 Carl B. Feldbaum, President, Biotechnology Industry Organization (BIO), on the development of BIO and the biotech industry during his tenure.
Issue 40: June 18, 2004 Donald W. Moran, President, The Moran Company, on New York Attorney General Eliot Spitzer’s fraud suit against GlaxoSmithKline.	Issue 37: May 28, 2004 Frank F. Bilstein (Left), Partner, and Razmic S. Gregorian, Jr. (Right), Director, Simon-Kucher & Partners, on the impact of the Medicare legislation on the environment for drug pricing in the U.S.
Issue 36: May 21, 2004 Robert Monaghan (Left), CEO, and Lawrence K. Cohen (Right), Vice Chairman, Zyomyx Inc., on the use of protein chips in drug development.	Issue 35: May 14, 2004 Viren Mehta, Managing Member, Mehta Partners LLC, on the merits of the Sanofi-Aventis merger .
Issue 34: May 7, 2004 John Rother, Director of Policy and Strategy, AARP, on the new Medicare drug discount cards and legislative reform priorities for Medicare.	Issue 32: April 23, 2004 Merrill Goozner, Journalist and Project Director, Center for Science in the Public Interest, on his new book, The $800 Million Pill.
Issue 31: April 16, 2004 Josef H. von Rickenbach, Chairman and CEO, PAREXEL International, on current trends in clinical development.	Issue 30: April 9, 2004 Scott Gottlieb, M.D.,Director of Medical Policy Development, FDA, on Mark McClellan’s tenure at the FDA. .
ssue 29: April 2, 2004 Wayne Koberstein, Contributing Editor, Contract Pharma, on globalization, consolidation, and pharmaceutical market strategies.	Issue 28: March 26, 2004 Barbara Yanni, Chief Licensing Officer and Vice President, Merck & Co., Inc., on Merck’s in-licensing activities.
Issue 27: March 19, 2004 Steven Rauscher, President and CEO, Genome Therapeutics, on the market launch of Factive.	Issue 26: March 12, 2004 Richard Trabert, Public affairs consultant and faculty member at Boston College’s Center for Corporate Citizenship, on social initiatives in the pharmaceutical industry.
Issue 25: March 5, 2004 Lowell E. Schnipper, M.D., Harvard Medical School Professor and Chief of Hematology and Oncology at Beth Israel Deaconess Medical Center, on synergies between new and existing treatments in oncology.	Issue 24: February 27, 2004 Soichi Matsuno, Chairman, Eisai Inc., on Eisai’s strategy in the U.S. market.
Issue 23: February 20, 2004 Donald O. Beers, Partner, Arnold & Porter, on polymorph patents.	Issue 22: February 13, 2004 Ken Araki, Pharmaceutical Industry Global Research Director, Nomura Securities International, on the forces shaping change in the pharmaceutical industry.
Issue 21: February 6, 2004 Jean-Paul Modde, Group President, Dendrite International, Inc., on new trends in CRM in the pharmaceutical industry.	Issue 19: January 23, 2004 Kevin Goodno, Commissioner, Minnesota Department of Human Services, on Minnesota’s initiatives toward prescription drug importation.
Issue 18: January 16,2004 Preston Henske, Vice President, Bain & Company, on building a new business model in the pharmaceutical industry.	Issue 15: December 12, 2003 Kenneth S. Abramowitz, Senior Advisor, The Carlyle Group, on the impact of Medicare reforms on the HMO industry.
Issue 14: December 5, 2003 Anthony Robbins, M.D., Professor of Public Health, Tufts University School of Medicine, on Medicare reform in historical perspective.	Issue 12: November 21, 2003 Louis M. Solomon, Partner, Proskauer Rose LLP, on Hatch-Waxman reforms.
Issue 11: November 14, 2003 Sharon Treat, Senate Majority Leader, State of Maine, on Maine’s initiatives to lower the cost of prescription drugs.	Issue 10: November 7, 2003 Nick Naclerio, President, ParAllele BioSciences, on pushing the boundaries of high-throughput SNP genotyping.
Issue 9: October 31, 2003 Vibeke Strand, M.D., Adjunct Clinical Professor, Division of Immunology, Stanford University, on new treatment therapies for rheumatiod arthritis.	Issue 7: October 17, 2003 Christopher D. Hook, Director for RFID Market Development & Deborah H. Murphy, Life Sciences Market Development Manager, Zebra Technologies, on technologies for pharmaceutical supply chains.
Issue 6: October 10, 2003 Brian G. Atwood, Managing Director, Versant Ventures, on biotech venture capital investing and market cycles.	Issue 5: October 3, 2003 Glenn Rice, Vice President for Biopharmaceutical Sciences, SRI International, on bridging the gap from university research labs to clinical trials.
Issue 4: September 26, 2003 Eric Lindsey, Vice President for Business Development, PDI Inc., on salesforce outsourcing.	Issue 3: September 19, 2003 Jack Trout, President, Trout & Partners, Ltd., on product positioning through DTC advertising.
Issue 2: September 12, 2003 Tom Heyman, Executive Vice President for Business Development, Johnson & Johnson, on J&J’s in-licensing activities.	Issue 1: September 5, 2003 Paula Campbell Evans, Partner, Palmer & Dodge LLP, on the regulatory prospects for generic biologics.